neutralizing antibody to IL-6

A neutralizing antibody to IL-6 is a therapeutic monoclonal antibody designed to bind specifically to interleukin-6 (IL-6), a key pro-inflammatory cytokine. By binding to IL-6, these antibodies prevent its interaction with the IL-6 receptor (IL-6R) and the gp130 signal transducer, thereby blocking downstream signaling pathways such as the JAK/STAT pathway. This inhibition suppresses inflammatory responses, immune cell activation, and tumor-promoting microenvironments. Several anti-IL-6 neutralizing antibodies have been developed, including siltuximab (approved for multicentric Castleman disease), olokizumab, and sirukumab, which are investigated or approved for autoimmune diseases like rheumatoid arthritis and various cancers.

Other names

anti-IL-6 antibodyanti-IL6 antibodyanti-IL 6 antibodyanti-IL-6 monoclonal antibodyanti-IL6 monoclonal antibodyanti-IL 6 monoclonal antibodyanti-IL-6 neutralizing antibodyanti-IL6 neutralizing antibodyanti-IL 6 neutralizing antibodyIL-6 antagonistIL6 antagonistIL 6 antagonistIL-6 inhibitorIL6 inhibitorIL 6 inhibitorIL-6 neutralizing antibodyIL6 neutralizing antibodyIL 6 neutralizing antibody